Milestone Pharmaceuticals, Inc. (MIST)
0.6482
-0.05
(-7.76%)
USD |
NASDAQ |
Oct 23, 16:00
0.65
0.00 (0.00%)
After-Hours: 20:00
Milestone Pharmaceuticals Enterprise Value : 51.92M for Oct. 23, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 23, 2026 | 51.92M |
| October 22, 2026 | 58.71M |
| October 21, 2026 | 57.79M |
| October 20, 2026 | 60.67M |
| October 19, 2026 | 58.38M |
| October 16, 2026 | 59.28M |
| October 15, 2026 | 70.14M |
| October 14, 2026 | 69.32M |
| October 13, 2026 | 66.56M |
| October 12, 2026 | 71.51M |
| October 09, 2026 | 66.46M |
| October 08, 2026 | 59.88M |
| October 07, 2026 | 65.49M |
| October 06, 2026 | 66.36M |
| October 05, 2026 | 68.26M |
| October 02, 2026 | 72.03M |
| October 01, 2026 | 72.78M |
| September 30, 2026 | 79.00M |
| September 29, 2026 | 73.31M |
| September 28, 2026 | 70.25M |
| September 25, 2026 | 69.38M |
| September 24, 2026 | 70.19M |
| September 23, 2026 | 78.54M |
| September 22, 2026 | 85.89M |
| September 21, 2026 | 85.49M |
| Date | Value |
|---|---|
| September 18, 2026 | 85.24M |
| September 17, 2026 | 85.71M |
| September 16, 2026 | 81.93M |
| September 15, 2026 | 86.72M |
| September 14, 2026 | 89.42M |
| September 11, 2026 | 93.24M |
| September 10, 2026 | 101.95M |
| September 09, 2026 | 104.44M |
| September 08, 2026 | 111.28M |
| September 04, 2026 | 120.62M |
| September 03, 2026 | 121.87M |
| September 02, 2026 | 118.13M |
| September 01, 2026 | 113.15M |
| August 31, 2026 | 115.64M |
| August 28, 2026 | 115.64M |
| August 27, 2026 | 119.38M |
| August 26, 2026 | 118.13M |
| August 25, 2026 | 115.64M |
| August 24, 2026 | 100.70M |
| August 21, 2026 | 102.57M |
| August 20, 2026 | 99.46M |
| August 19, 2026 | 105.68M |
| August 18, 2026 | 104.44M |
| August 17, 2026 | 108.17M |
| August 14, 2026 | 108.17M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| InMed Pharmaceuticals, Inc. | 5.455M |
| NervGen Pharma Corp. | 91.00M |
| Appili Therapeutics, Inc. | 10.20M |
| Clearmind Medicine, Inc. | -1.539M |
| Lexaria Bioscience Corp. | 1.165M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -28.61M |
| Revenue (Quarterly) | 0.559M |
| Total Expenses (Quarterly) | 29.17M |
| EPS Diluted (Quarterly) | -0.2063 |
| Gross Profit Margin (Quarterly) | 84.08% |
| Profit Margin (Quarterly) | -5.12K% |
| Earnings Yield | -107.0% |
| Normalized Earnings Yield | -107.03 |